Suneel Gupta sold $5.6M of PTGX
Chief Development Officer at Protagonist Therapeutics, Inc. 122,628 shares at an average of $45.96, traded Nov 25, 2024, filed Nov 27, 2024.
Score components
- +15RoleOfficer
- +25Trade size$5.6M at market
- +10Share of holdings soldSold 34% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.3%, 3m -19.6%, 6m +1.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-123807, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | MOption exercise Common Stock | +45,000 | $7.38 | $332k | 229,611 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Common Stock | +45,000 | $8.02 | $361k | 274,611 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Common Stock | +85,000 | $7.80 | $663k | 359,611 | Nov 27, 2024 |
| Nov 25, 2024 | SOpen-market sale Common Stock | -103,437 | $46.04 | $4.8M | 256,174 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Common Stock | +30,000 | $12.17 | $365k | 286,174 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -19,191 | $45.50 | $873k | 266,983 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Common Stock | +450 | $12.17 | $5,477 | 267,433 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (right to buy)derivative | -45,000 | $0.00 | $0 | 0 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (right to buy)derivative | -45,000 | $0.00 | $0 | 0 | Nov 27, 2024 |
| Nov 25, 2024 | MOption exercise Stock Option (right to buy)derivative | -85,000 | $0.00 | $0 | 0 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Stock Option (right to buy)derivative | -30,000 | $0.00 | $0 | 93,750 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Stock Option (right to buy)derivative | -450 | $0.00 | $0 | 93,300 | Nov 27, 2024 |
Related signals
Other insiders at Protagonist Therapeutics, Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $8.3M 58,629 shares | -50% | |
| 20Weak | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $18M 125,000 shares | -22% | |
| 34Weak | PTGXsell Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $185k 1,750 shares | -3% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $2.6M 24,765 shares | -29% | |
| 45Moderate | Protagonist Therapeutics, Inc | Arturo Molina Md Chief Medical Officer | $1.6M 15,000 shares | -15% | |
| 50Moderate | Protagonist Therapeutics, Inc | Harold E Selick director | $2.5M 24,000 shares | -28% | |
| 55Moderate | Protagonist Therapeutics, Inc | Dinesh Ph D Patel V President and CEO | $5.5M 54,700 shares | -10% | |
| 53Moderate | Protagonist Therapeutics, Inc | Lewis T Williams director | $1.5M 18,000 shares | -70% | |
| 60Notable | Protagonist Therapeutics, Inc | William D. Waddill director | $1.7M 20,000 shares | -72% | |
| 57Moderate | Protagonist Therapeutics, Inc | Asif Ali Chief Financial Officer | $3.8M 46,203 shares | -43% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.